Target-mediated drug disposition model and its approximations for antibody–drug conjugates

An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling in Patients with HER2-Positive Metastatic Breast Cancer

(2013) Dan Lu et al.   CLINICAL PHARMACOKINETICS

Maturing antibody–drug conjugate pipeline hits 30

(2013) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Semi-mechanistic Population Pharmacokinetic Model of Multivalent Trastuzumab Emtansine in Patients with Metastatic Breast Cancer

(2012) V L Chudasama et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics

(2009) Leonid Gibiansky et al.   Expert Opinion on Drug Metabolism & Toxicology

Selection between Michaelis–Menten and target-mediated drug disposition pharmacokinetic models

(2009) Xiaoyu Yan et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Approximations of the target-mediated drug disposition model and identifiability of model parameters

(2008) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS